Key result
Anticoagulation with recombinant human tissue-factor-pathway inhibitor abolished thrombin generation but did not improve indexes of myocardial injury during reperfusion in isolated rabbit hearts.
Why the study?
Does recombinant human tissue-factor-pathway inhibitor prevent ischemia/reperfusion injury in isolated Langendorf-perfused rabbit hearts?
Does recombinant human tissue-factor-pathway inhibitor prevent ischemia/reperfusion injury in isolated Langendorf-perfused rabbit hearts?
Inhibition of tissue-factor-mediated coagulation does not mitigate ischemia/reperfusion injury in isolated rabbit hearts, suggesting coagulation does not play a major role in this specific injury model.
Does not support TFPI for limiting reperfusion injury; leaves open coagulation's role in more complex in vivo models.
BACKGROUND: Production of oxygen free radicals, and activation of neutrophils and plasma complement contribute to myocardial reperfusion injury, but the role of coagulation has not been assessed. OBJECTIVE: To characterize tissue-factor-mediated generation of thrombin and its association with tissue injury during reperfusion from normothermic ischemia of isolated, Langendorf-perfused rabbit hearts. METHODS: Activation of coagulation was assessed by addition of 12% rabbit plasma and human fibrinogen to Krebs-Henseleit-buffer perfusate with measurement of levels of human fibrinopeptide A (hFPA) in the heart effluent as an index of thrombin-mediated formation of fibrin. RESULTS: Concentrations of hFPA in the effluent were minimal during non-ischemic perfusion (5 +/- 5 ng/ml, n=6) and during 50 min of ischemia (13 +/- 3 ng/ml, n=6), but increased markedly during the first 20 min of reperfusion (to 41 +/- 29 ng/ml, P=0.03 versus before reperfusion). Addition to the perfusate of 10 microg/ml recombinant human tissue-factor-pathway inhibitor, the physiologic inhibitor of tissue-factor-mediated coagulation, abolished increases in the level of hFPA after reperfusion. However, indexes of myocardial injury manifested during reperfusion, including decrease in recovery of left ventricular pressure developed, increase in left ventricular end-diastolic pressure, and increase in activity of creatine kinase in the heart effluent, were not improved by anticoagulation with recombinant human tissue-factor-pathway inhibitor. CONCLUSION: Our results do not support the hypothesis that coagulation plays a major role in ischemia/reperfusion injury of Langendorf-perfused rabbit hearts.
No takes yet. Share an insight, caveat, or question.
Armaganian et al. (2000) studied Myocardial ischemia/reperfusion injury. Recombinant human tissue-factor-pathway inhibitor vs. No inhibitor was evaluated on Indexes of myocardial injury (recovery of left ventricular pressure developed, left ventricular end-diastolic pressure, and creatine kinase activity). Anticoagulation with recombinant human tissue-factor-pathway inhibitor abolished thrombin generation but did not improve indexes of myocardial injury during reperfusion in isolated rabbit hearts.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: